Genenta Science (GNTA) Competitors $3.88 +0.06 (+1.57%) As of 03:23 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. TNXP, PROK, ANNX, PRTA, RNAC, PVLA, CRVS, AVIR, IMMP, and TSVTShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Tonix Pharmaceuticals (TNXP), ProKidney (PROK), Annexon (ANNX), Prothena (PRTA), Cartesian Therapeutics (RNAC), Palvella Therapeutics (PVLA), Corvus Pharmaceuticals (CRVS), Atea Pharmaceuticals (AVIR), Immutep (IMMP), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Its Competitors Tonix Pharmaceuticals ProKidney Annexon Prothena Cartesian Therapeutics Palvella Therapeutics Corvus Pharmaceuticals Atea Pharmaceuticals Immutep 2seventy bio Tonix Pharmaceuticals (NASDAQ:TNXP) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends. Does the MarketBeat Community favor TNXP or GNTA? Tonix Pharmaceuticals received 335 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 60.53% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34260.53% Underperform Votes22339.47% Genenta ScienceOutperform Votes787.50% Underperform Votes112.50% Which has better valuation and earnings, TNXP or GNTA? Genenta Science has lower revenue, but higher earnings than Tonix Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.04M25.20-$116.66M-$1.96 thousand-0.02Genenta ScienceN/AN/A-$12.60MN/AN/A Is TNXP or GNTA more profitable? Genenta Science has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Genenta Science's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% Genenta Science N/A N/A N/A Does the media favor TNXP or GNTA? In the previous week, Tonix Pharmaceuticals had 12 more articles in the media than Genenta Science. MarketBeat recorded 14 mentions for Tonix Pharmaceuticals and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.78 beat Tonix Pharmaceuticals' score of 0.51 indicating that Genenta Science is being referred to more favorably in the news media. Company Overall Sentiment Tonix Pharmaceuticals Positive Genenta Science Positive Do analysts recommend TNXP or GNTA? Tonix Pharmaceuticals currently has a consensus target price of $585.00, indicating a potential upside of 1,593.69%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 544.33%. Given Tonix Pharmaceuticals' higher possible upside, equities research analysts clearly believe Tonix Pharmaceuticals is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, TNXP or GNTA? Tonix Pharmaceuticals has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Do insiders and institutionals hold more shares of TNXP or GNTA? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryTonix Pharmaceuticals and Genenta Science tied by winning 7 of the 14 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.97M$3.12B$5.61B$8.62BDividend YieldN/A1.57%5.28%4.17%P/E RatioN/A32.9027.1419.96Price / SalesN/A466.20411.83157.63Price / CashN/A168.6838.2534.64Price / Book3.213.427.064.69Net Income-$12.60M-$72.35M$3.23B$248.14M7 Day Performance-9.77%7.27%2.67%2.39%1 Month Performance-5.94%17.53%8.82%6.05%1 Year Performance23.17%-17.27%31.44%13.60% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.7712 of 5 stars$3.88+1.6%$25.00+544.3%+15.8%$70.97MN/A0.007Short Interest ↓TNXPTonix Pharmaceuticals3.3562 of 5 stars$39.20-3.6%$585.00+1,392.3%-82.3%$287.14M$10.04M-0.0150News CoverageGap DownPROKProKidney2.4649 of 5 stars$0.98+0.2%$4.50+359.2%-61.4%$286.84M$306K-1.783Positive NewsGap DownANNXAnnexon2.4678 of 5 stars$2.59-0.4%$12.50+382.6%-53.8%$284.16MN/A-2.4760Positive NewsAnalyst RevisionPRTAProthena3.695 of 5 stars$5.25-3.0%$31.50+500.0%-75.1%$282.59M$137.94M-2.28130Short Interest ↓Analyst RevisionHigh Trading VolumeRNACCartesian Therapeutics1.9242 of 5 stars$10.85-1.6%$43.00+296.3%-66.1%$281.60M$34.17M-0.2164Positive NewsAnalyst RevisionPVLAPalvella Therapeutics4.0465 of 5 stars$26.63+4.8%$46.29+73.8%N/A$280.82M$42.81M-2.20N/APositive NewsAnalyst RevisionCRVSCorvus Pharmaceuticals2.6686 of 5 stars$4.04+3.3%$15.00+271.3%+110.3%$275.40MN/A-4.3430News CoverageAnalyst RevisionAVIRAtea Pharmaceuticals3.3763 of 5 stars$3.21+0.9%$6.00+86.9%-19.1%$274.71MN/A-1.5570Positive NewsIMMPImmutep1.4091 of 5 stars$1.84-1.1%$7.00+280.4%-31.7%$268.71M$5.14M0.002,021TSVT2seventy bio1.2176 of 5 stars$5.00flat$5.00N/A$266.15M$48.37M-2.69440 Related Companies and Tools Related Companies Tonix Pharmaceuticals Competitors ProKidney Competitors Annexon Competitors Prothena Competitors Cartesian Therapeutics Competitors Palvella Therapeutics Competitors Corvus Pharmaceuticals Competitors Atea Pharmaceuticals Competitors Immutep Competitors 2seventy bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNTA Stock Free GNTA Stock Alerts